Table 2.
Frequency of BCR-ABL transcript types among CML patient groups (n = 21)†.
| Patient group | BCR-ABL transcript types | |||
|---|---|---|---|---|
| b2a2 | b3a2 | b3a3 | e1a3 | |
| Imatinib-treated patients (n = 15) | P = 0.454∗ | P = 0.047∗ | P = 0.657∗ | P = 0.342∗ |
| BCR-ABL ≤ 0.1% (n = 9) | 6 of 10 (60%) | 1 of 10 (10%) | 1 of 10 (10%) | 2 of 10 (20%) |
| BCR-ABL > 0.1% (n = 6) | 3 of 8 (37.5%) | 4 of 8 (50%) | 1 of 8 (12.5%) | 0 of 8 (0%) |
|
| ||||
| Noncompliant patients (n = 6) | 5 of 6 | 0 of 6 | 1 of 6 | 0 of 6 |
†Dual transcripts were detected in three patients, which explains reporting 24 transcripts in 21 patients.
∗Independence of BCR-ABL transcript types among imatinib-treated patients according to their molecular response was analyzed by Fisher's exact test. P value < 0.05 was considered significant.